Yuki Noguchi
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on everything from vaccination and racial inequities in access to health, to cancer care, obesity and mental health.
Since joining NPR in 2008, Noguchi has also covered a range of business and economic news, with a special focus on the workplace — anything that affects how and why we work. In recent years, she has covered the rise of the contract workforce, the #MeToo movement, the Great Recession and the subprime housing crisis. In 2011, she covered the earthquake and tsunami in her parents' native Japan. Her coverage of the impact of opioids on workers and their families won a 2019 Gracie Award and received First Place and Best In Show in the radio category from the National Headliner Awards. She also loves featuring offbeat topics, and has eaten insects in service of journalism.
Noguchi started her career as a reporter, then an editor, for The Washington Post.
Noguchi grew up in St. Louis, inflicts her cooking on her two boys and has a degree in history from Yale.
-
A new drug for pancreatic cancer gives some hope for one of the most dire types of cancer.
-
The American Cancer Society is changing its screening recommendations for colorectal cancer, suggesting adults begin screening at age 45 and adding blood-based tests as an option.
-
Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have more reason to hope than ever before. -
Unlike many cancers, colorectal cancer has become more lethal for people at younger ages. Doctors are sleuthing out why. -
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message. -
James Van Der Beek's death at age 48 highlights a sad statistic: More people under 50 are getting colorectal cancer.
-
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders. -
As GLP-1 drugs become more available, some people might use them despite not having excess weight.
-
GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to the future of this treatment method.
-
Immigrants make up about a quarter of all the country's doctors. New policies are making it harder and less appealing for foreign-born physicians to come to the U.S.
